GlobeNewswire by notified

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Share

COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The Company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its personalized DNA-based immunotherapy, EVX-02. The results are summarized below.

“We are thrilled to announce promising interim data from the first eight patients in our Phase 1/2a study of EVX-02. We believe that these results serve as validation of our DNA technology for personalized cancer immunotherapy. All patients demonstrated a specific T-cell immune response induced by the treatment, confirming the potential capabilities of our AI platform technology. And importantly, the treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed,” said CEO Per Norlén.

Personalized cancer immunotherapy, like EVX-02, is particularly challenging to produce because a new and unique drug is manufactured for each patient.

“This is a tremendous achievement. Our team has successfully completed this complex process, from biopsy, through genome sequencing, a selection of the most promising cancer targets through our AI platform technology, to manufacturing, quality testing, and drug product production and delivery. And they succeeded with every single step for each patient,” says Mr. Norlén.
“The promising EVX-02 data, demonstrating both proof of mechanism and an encouraging safety profile, give us exactly what we need for our upcoming clinical trial of EVX-03 and our next-generation DNA technology.”

Interim results in summary:

  • Safety: Treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed in relation to EVX-02 treatment.
  • EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for our DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides.
  • The T-cell responses were robust and long-lasting.

A full clinical trial report for the EVX-02 Phase 1 study is expected in the second quarter of 2023.

About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. A proprietary and scalable AI technology is used to decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including patient-specific cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees.

Evaxion Biotech A/S
Per Norlén
Chief Executive Officer (CEO)

For more information, please contact
Katrine Hertz Mortensen
VP, Communications and Public Relations
khm@evaxion-biotech.com
+45 3010 0203

Source: Evaxion Biotech

Forward-looking statement

This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, besides those of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and the emergence and prevalence of COVID-19 variants, such as the Delta and Omicron variant and certain related variants such as the Omicron BA.4 and BA.5 variants, risks associated with the invasion of the Ukraine by Russia and other risks and uncertainties affecting the Company’s business operations and financial condition.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Annual Report on Form 20-F filed on March 31, 2022 and the Company’s current and future reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Innofactor Plc: Share Repurchase 1.2.20231.2.2023 17:30:00 CET | Press release

Innofactor Plc Announcement 1.2.2023Innofactor Plc: Share Repurchase 1.2.2023In the Helsinki Stock ExchangeTrade date 1.2.2023Bourse trade BuyShare IFA1VAmount 6,200SharesAverage price/ share 1.1752EURTotal cost 7,286.24EURInnofactor Plc now holds a total of 1 358 836 sharesincluding the shares repurchased on 1.2.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comwww.innofactor.com Attachment Innofactor_1.2_trades

RULE 2.9 ANNOUNCEMENT1.2.2023 16:40:00 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 1 FEBRUARY 2023 PAYPOINT PLC ("PAYPOINT") RULE 2.9 ANNOUNCEMENT In accordance with Rule 2.9 of The City Code on Takeovers and Mergers, the Company confirms that, as at the date and time of this announcement, its issued share capital consists of 68,986,938 ordinary shares of 1/3 pence each, which carry voting rights of one vote per share. The Company does not hold any ordinary shares in treasury. The International Securities Identification Number for the Company's ordinary shares is GB00B02QND93. Enquiries: PayPoint plc Brian McLelland, Company Secretary +44(0)7721211100

Treasury Bond Auction Announcement - RIKB 26 1015 - RIKS 37 01151.2.2023 16:31:00 CET | Press release

SeriesRIKB 26 1015RIKS 37 0115ISINIS0000034874IS0000033793Maturity Date10/15/202601/15/2037Auction Date02/03/202302/03/2023Settlement Date02/08/202302/08/202310% addition02/07/202302/07/2023 On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website. For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.

The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions1.2.2023 15:40:00 CET | Press release

Talenom Plc, Stock Exchange Release 1 February 2023 at 16:40 EET The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions Talenom Plc announced two acquisitions on 1 February 2023. Part of the purchase prices will be paid in cash and part with new shares of Talenom Plc subscribed in a directed share issue. The transaction prices are not disclosed. As part of the transactions, Talenom has decided to issue 50,825 new shares in a directed share issue for the sellers of the acquisition targets, i.e., BKF Asesores, S.L. and R2 Redovisning Ab. The subscription date for the shares is 1 February 2023. The number of new shares to be issued corresponds with some 0.11 percent of all Talenom Plc's shares prior to the share issue. After the registration of the new shares the total number of shares in Talenom Plc is 44,986,213 shares. The new shares will carry shareholder rights as of their registration day, estimated on 3 February 2023. The shares issued i

Talenom expands its operations in Spain by acquiring an accounting firm in Madrid1.2.2023 15:35:00 CET | Press release

Talenom Plc, press release 1 February 2023 at 16:35 EET Talenom expands its operations in Spain by acquiring an accounting firm in Madrid Talenom Plc has agreed to acquire the entire share capital of BKF Asesores, S.L., an accounting firm operating in Madrid, Spain. The acquired business will be transferred to Talenom on 1 February 2023. BKF Asesores, S.L. provides accounting, payroll and advisory services mainly to SMEs. The net sales transferred to Talenom from the acquired business is some EUR 0.7 million annually. The company employs a total of nine persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 85